300314.SZ
戴维医疗
SZSE · Healthcare · C 制造业 · CN
CNY 12.45
−5.03%Year over year
Reported trailing growth
- Revenue
- +16.8%
- EBITDA
- —
- EBIT
- +68.3%
- EPS
- +78.1%
- Free cash flow
- +177.0%
- Operating cash flow
- +16.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.9%
- EBITDA
- -2.5%
- EBIT
- -4.1%
- Net income
- -3.7%
- EPS
- -4.1%
- Free cash flow
- -17.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026